Despite a volatile year in terms of M&As and product lawsuits, overall U.S. pharmaceutical sales continue to grow. However, some of the top-selling prescription medicines are set to lose patent protection during 2010 and 2011. Manufacturers and marketers of these products are taking advantage of their remaining patented months and lofty sales status by continuing to penetrate emerging regions and marketing their products' additional indications.
The top 500 Rx medicine entries of 2009 generated total sales of about $423 billion compared with the same total for the 500 leaders of 2008, $397 billion for the class of 2007, and $354 billion for the 500 members of 2006. For the 500 top sellers based on 2009 sales and constant exchange rates, their joint 2008 sales amounted to $348 billion and their 2007 tally came in at $346 billion.
The data are sorted and presented in three formats: by the highest product 2009 global sales, by the companies that report sales for these products, and by the primary disease/medical use that each product treats.
The charts provide the following information:
• 2009 sales rank for each medicine
• 2009, 2008 and 2007 worldwide sales for each medicine
• Companies that report sales for each medicine
• At least one primary disease/medical use that each medicine treats
• First approval date or launch date of each medicine, and in some instances the region of occurrence is provided.